(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

Trial Profile

(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs PAC 1 (Primary)
  • Indications Haematological malignancies; Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Vanquish Oncology
  • Most Recent Events

    • 10 Oct 2017 Status changed from active, no longer recruiting to recruiting.
    • 17 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top